Federal regulators have cleared a novel artificial intelligence and biometric tool designed to assist clinicians in identifying children with autism, marking another step forward in the technological landscape of developmental disability screening.
The Food and Drug Administration cleared the diagnostic support tool, known as Neurora, to inform clinical decisions regarding children between the ages of 18 months and 12 years. Developed by Argus Cognitive, Inc., the software system relies on an analysis of more than 100 distinct biometrics to help assess whether a child displays behavioral markers consistent with autism spectrum disorder.
The clearance arrives at a critical time for families navigating the healthcare system. According to estimates from the Centers for Disease Control and Prevention, autism now affects approximately 1 in 31 children. Despite high prevalence rates, many families encounter extensive waiting lists to have their children evaluated by specialists. Furthermore, federal data shows that the median age of an autism diagnosis hovers at just under four years old, highlighting an ongoing need for reliable tools that can streamline the evaluation process and support earlier identification.
Under the operational framework approved by federal regulators, clinicians can upload video and audio recordings gathered during standard behavioral assessments directly into the secure Neurora portal. The proprietary tool then measures a wide array of behavioral indicators, including facial expressions, voice patterns, and eye gaze dynamics. By processing these data points, Neurora evaluates how a child’s specific behavioral profile compares against extensive datasets representing children both with and without autism.
Developers emphasize that the software is not intended to replace professional clinical evaluation or provide a standalone diagnosis. Instead, the results generated by the tool are designed to be considered in conjunction with other clinical findings and professional medical judgment.
Dr. Attila Meretei, the chief executive officer and co-founder of Argus Cognitive, emphasized the supportive role the technology is meant to play within existing medical workflows. He noted that the company built Neurora specifically to support clinicians who are actively evaluating children for autism. According to Meretei, the software is designed to function seamlessly within the assessment procedures that medical professionals already utilize, requiring no disruptive protocol changes or specialized proprietary hardware. He added that the system operates in a fully automated fashion, with the overarching goal of reinforcing every clinical diagnosis with robust, quantitative evidence.
The development of Neurora did not happen in a vacuum. Argus Cognitive reported that the creation and refinement of the tool received crucial financial and strategic backing from a National Institutes of Health grant geared toward supporting entrepreneurial health tech innovations.
Scientific validation for the system has also been advancing through peer-reviewed research. A study published earlier this year in scientific journals demonstrated the software’s capability in distinguishing between neurotypical children and those on the autism spectrum. According to the research findings, the tool successfully distinguished between the two groups in nearly 78 percent of cases, providing empirical backing for its integration into clinical settings.
Neurora joins a small but growing roster of FDA-cleared technological devices designed to assist diagnosticians in the complex landscape of autism evaluation. The regulatory green light places Neurora alongside other pioneering tools that have cleared federal hurdles in recent years. For instance, the FDA previously approved the EarliPoint Evaluation for ASD, which utilizes specialized eye-tracking technology to analyze a child’s visual behavior during assessments. Regulators also previously cleared Canvas Dx, an algorithm-driven system that analyzes information submitted by both parents and healthcare providers, alongside video submissions, to help guide clinical decisions regarding diagnoses.
As these tools become more integrated into modern medical practice, public health advocates hope they will help alleviate the bottlenecks currently plaguing pediatric specialty clinics. Long evaluation wait times remain a persistent barrier for families seeking early intervention services, which are widely recognized as vital for maximizing long-term developmental outcomes. By equipping clinicians with quantitative, AI-supported biometric evidence, developers of tools like Neurora aim to bring greater efficiency, objectivity, and confidence to the diagnostic process, ultimately helping children and their families access the support and resources they need much earlier in life.
